This partnership leverages Taiwan Bio’s world-class expertise in cellular therapy manufacturing and TRACT Therapeutics’ innovative immune modulating regulatory T cell therapy platform. By combining their strengths, the companies are set to explore new frontiers in enabling allogeneic tissue transplant with a focus on enhanced patient outcomes and improved quality of life. The upcoming Phase 2 trial builds upon the promising results from a Phase 1 study which demonstrated an excellent safety profile and encouraging efficacy signals with TRACT’s autologous Treg product, TregCel^TM.

"We believe that this collaboration holds tremendous promise for patients seeking better therapeutic options," said Cyrus Yang, COO of Taiwan Bio. "Together with TRACT Therapeutics, we can bring a synergy of technology and experience to accelerate the development of transformational Treg therapies."

John Flavin, CEO of Portal Innovations member company, TRACT Therapeutics, added, “Our collaboration with Taiwan Bio is a strategic milestone that paves the way for mutual success. TRACT recognizes the importance of a state-of-the art GMP cell manufacturing facility to advance the development of our Treg therapy and found the best-in-class capabilities of the Taiwan Bio manufacturing team aligns perfectly with our needs. By working with Taiwan Bio, we are bringing the best of both worlds together—manufacturing excellence and a cutting-edge, personalized cellular therapy for patients. Our Phase 2 trial represents a significant step forward in our mission to provide solid organ transplant patients with better treatment options."

Joseph R Leventhal, MD, PhD, Fowler McCormick Professor of Surgery at Northwestern University and Scientific Founder of TRACT Therapeutics, stated, “There is a critical need to develop better treatments for patients undergoing a solid organ transplant. TRACT’s regulatory T cell therapy platform holds the promise to revolutionize our approach to organ transplantation by not only preventing organ rejection but also enabling us to reduce the reliance on toxic immunosuppressive drugs. By harnessing the power of regulatory T cells, we can provide our patients with the potential for long-term, rejection-free transplant success while minimizing the adverse effects associated with traditional immunosuppression.”

Matthew Cooper, MD, Chief of Transplantation at the Medical College of Wisconsin added, “This therapy represents a potential pivotal shift in the field of transplantation, offering new hope for improved outcomes and enhanced quality of life for all patients receiving solid organ transplants."

The Phase 2 clinical trial represents the first collaborative effort between the two companies, and further updates on the trial's progress will be shared in the coming months.